Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
about
Maximising the potential of AKT inhibitors as anti-cancer treatmentsAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivityARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.AKT/PKB Signaling: Navigating the Network.The protective value of miR-204-5p for prognosis and its potential gene network in various malignancies: a comprehensive exploration based on RNA-seq high-throughput data and bioinformatics.Are there physicochemical differences between allosteric and competitive ligands?In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).Mutational Analysis of Oncogenic AKT1 Gene Associated with Breast Cancer Risk in the High Altitude Ecuadorian Mestizo Population
P2860
Q28072254-AAC6EFD7-BFB6-4BDC-8A40-9716FC6DDFFAQ28080599-FB6EF1D5-C523-488C-B949-2C4BDCE0A770Q33601377-2495E6D8-32C6-47AA-BFC2-2E6880A1D846Q36392979-F4C2D0BE-7D38-44AF-834C-2D10445F19A9Q36782409-4D517CC2-DEF0-4B2C-8569-1E9CE526BADAQ37618816-AC81002D-8517-461F-B0F8-CC4EBC41A5ECQ38793867-4843BF58-8058-4D37-BFD9-B3FC1338795CQ39255027-ACB91F6F-D275-4551-8C82-D415E6E0DC79Q47149216-F4638F7D-76BB-4D0B-B7C8-D2237FD5603DQ47384821-6194D495-C7EB-4260-B00F-D4F160E3BBACQ52726054-E05D3498-4CB0-4E7E-97EA-F4B7073DD6C6Q57092342-A0D78A39-3AD9-48C8-85AA-ADAAF0FC1CD3
P2860
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@ast
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@en
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@nl
type
label
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@ast
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@en
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@nl
prefLabel
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@ast
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@en
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@nl
P2093
P2860
P1433
P1476
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
@en
P2093
Giovanni Abbadessa
Justin Meade
Michael J Wick
Ronald E Savage
Sudharshan Eathiraj
Terence Hall
P2860
P304
P356
10.1371/JOURNAL.PONE.0140479
P407
P577
2015-01-01T00:00:00Z